Arachidonic acid Clinical Trials

Size	Price	Qty
2ul	USD 127
5ul	USD 197

Clinical Trials

Numerous clinical trials evaluate arachidonic acid across diverse therapeutic and nutritional applications, spanning Phase 1 through Phase 4 interventional and observational studies. Sponsored by academic institutions such as Memorial Sloan Kettering Cancer Center and industrial partners like Fresenius Kabi, these protocols investigate conditions including essential fatty acid deficiency, parenteral nutrition-associated liver disease, infant nutritional requirements, coronary artery disease, and head and neck squamous cell carcinoma. Ranging from completed to active recruitment, trials evaluate interventions such as infant supplementation, intravenous lipid formulations, and cardiovascular modulation.

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT05380401	RECRUITING	Premature	The University of Texas Health Science Center at San Antonio	2023-03-09
NCT06827873	NOT_YET_RECRUITING	Influenza Vaccine Response	Tsinghua University	2025-02
NCT06366893	UNKNOWN	Infant, Premature, Diseases	Hospital Universitari Vall d'Hebron Research Institute	2024-03-04
NCT05191823	ACTIVE_NOT_RECRUITING	Preterm Birth; Child Development	Sarah Keim	2021-12-01
NCT06274788	Not yet recruiting	Parenteral Nutrition Associated Liver Disease (PNALD)\|Essential Fatty Acid Deficiency\|Malnutrition\|Pediatric ALL	Fresenius Kabi	2024-05-01	Phase 4
NCT05987384	COMPLETED	Rabies Vaccination Reaction	Tsinghua University	2023-05-03
NCT05788588	Active not recruiting	Parenteral Nutrition	Fujian Shengdi Pharmaceutical Co. Ltd.	2023-04-28	Phase 3
NCT04827251	Recruiting	Coronary Artery Disease	University of Sao Paulo\|Fundação de Amparo à Pesquisa do Estado de São Paulo	2022-09-01	Not Applicable
NCT05542147	Recruiting	Type 2 Diabetes\|Cardiovascular Diseases\|Pharmacogenomic Drug Interaction	Mario Luca Morieri\|University Hospital Padova	2022-07-03	Not Applicable
NCT01576783	COMPLETED	Preterm Birth; Child Development	Sarah Keim	2012-04-26	PHASE4
NCT00982462	COMPLETED	Infant Development	Retina Foundation of the Southwest	2011-01-20
NCT02219412	COMPLETED	Coronary Heart Disease	Yong Huo	2014-08	PHASE4
NCT02503020	COMPLETED	Impaired Psychomotor Development	Health Research Institute of Santiago	2011-07	PHASE2
NCT02092857	COMPLETED	Focus: Nutritional Requirements for Infants	University of Alberta	2009-12	PHASE1
NCT02144389	COMPLETED	Schistosomiasis; Bilharzia	dsm-firmenich Switzerland AG	2013-01
NCT01021215	COMPLETED	Tobacco Use Disorder	National Cancer Institute (NCI)	2010-05	PHASE1; PHASE2
NCT01154894	COMPLETED	Autism Spectrum Disorders	Ashiya University	2009-02
NCT01300130	COMPLETED	Prematurity of Fetus	Ludwig-Maximilians - University of Munich	1995-06

(data from https://clinicaltrials.gov, updated on 2025-09-24)

Check the Arachidonic acid product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

As an essential polyunsaturated fatty acid, arachidonic acid serves as a primary substrate for cyclooxygenase, lipoxygenase, and cytochrome P450 enzymes, leading to the biosynthesis of bioactive eicosanoid mediators including prostaglandins, thromboxanes, and leukotrienes that regulate inflammatory signaling, vascular tone, and cell survival. These downstream lipid signaling networks modulate cellular immunity, platelet aggregation, and membrane integrity, providing the physiological rationale for supplementing arachidonic acid in parenteral nutrition formulations and assessing its impact on pediatric lipid deficiency and cardiovascular conditions.

Appendix RUO and cGMP Quality Standards

Quality Dimension	RUO (Research Use Only)	cGMP (Current Good Manufacturing Practice)
Clinical Applicability	Prohibited in human clinical trials or medical diagnostics.	Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status	Non-regulated grade; exempt from drug manufacturing laws.	Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment	Unclassified analytical or research laboratories.	Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control	Basic purity and activity testing.	Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation	Basic equipment calibration; no process validation required.	Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance	Vendor self-declared without required formal QMS.	Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact	High risk of IND rejection if used as a critical raw material.	Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).